Acarix AB (publ) (ACARIX) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the q one twenty twenty six earnings call of Acarix. I appreciate everybody joining this morning. And before we kick off, it's important for us to all kind of understand and realize that the world is in a a very dynamic shift as we speak. The geopolitical tension, most permanently in The Middle East markets right now, are ongoing, and we don't see an end in sight. However, what I wanna rest assure is all operations from a Acarix standpoint are fully functional. While we do have a lot of entry and focus within the MENA Region, nothing has come to a stop. So things are moving along slower than expected. However, given the rhetoric and the challenges we face across the board globally, I think that everybody recognizes it, but it's important to make sure we address those, those situations as we continually press forward. Second, I'll apologize in advance. I have a mild cough due to my allergies, but nothing, to be concerned about. So let's go ahead and move into the deck. For all our new investors, thank you for joining. Just a quick update on who we are. This is we're a Carriage. We have the CatScore system, and we're we're really trying to revolutionize early onset diagnostics in the cardiovascular rent range. We have a point of care device that is fairly quick within ten minutes and can calculate a CAT score for patients feeling low to moderate chest pain or shortness of breath. We can quickly and very easily identify those things using high fidelity acoustics, listening into the arterial flow, and our negative predictive value is ninety six point two percent in The United States and ninety seven point two percent in The European markets. We have over fifteen years of r and d, over 45 patents, and we have over 6,000 patients in clinical tr...